RELMADA THERAPEUTICS, INC. (RLMD) News Headlines

▮ More

Date

Headline

8/9/2022 8:32:38 AM Relmada Therapeutics Receives FDA Fast Track Designation For REL-1017 As Monotherapy For Major Depressive Disorder

8/9/2022 8:30:00 AM Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder (Press Release)

4/29/2022 8:32:51 AM Relmada Therapeutics Announces Publication Of REL-1017 Preclinical Data In Frontiers In Pharmacology

4/29/2022 8:30:00 AM Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology (Press Release)

2/23/2022 8:15:38 AM Relmada Announces Positive Results Of Study Evaluating REL-1017 Vs Ketamine For Abuse Potential

2/23/2022 7:29:03 AM Relmada Announces Top-Line Results Of REL-1017 Vs Ketamine For Abuse Potential; Stock Up

12/22/2021 9:15:03 AM Relmada Announces Publication Of REL-1017 Phase 2 Study Results In American Journal Of Psychiatry

12/9/2021 10:36:12 AM Relmada Therapeutics Trading 8% Higher

12/9/2021 1:43:02 AM AZN's Antibody Authorized For COVID-19, RDUS Shrinks, ZYME On Watch, FDA Panel Snubs RETA

12/9/2021 1:37:19 AM Relmada Prices Upsized Public Offering Of 8.82 Mln Shares At $17/shr

12/8/2021 11:39:14 PM Relmada Therapeutics Prices Public Offering Of 8.82 Mln Shares At $17/Shr

10/4/2021 8:57:25 AM FDA Confirms Relmada Not Required To Conduct Two-Year Carcinogenicity Study To Support REL-1017 Data

10/4/2021 8:37:24 AM FDA Confirms Relmada Not Required To Conduct Two-Year Carcinogenicity Study

10/4/2021 8:30:00 AM Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder (Press Release)

7/27/2021 10:30:54 AM Relmada Therapeutics Gains 6% On Positive Results Of REL-1017

7/27/2021 7:42:43 AM Relmada Therapeutics Announces Top-Line Results Of Study Evaluating REL-1017 Vs Oxycodone For Abuse Potential

7/27/2021 7:35:00 AM Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential (Press Release)

7/20/2021 8:17:01 AM Relmada Therapeutics Announces Acquisition Of Commercial Rights To Psilocybin And Derivates Program From Arbormentis

7/20/2021 8:15:00 AM Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC (Press Release)

5/26/2021 8:29:51 AM Relmada Therapeutics To Present REL-1017 Clinical Data At 2021 ASCP Annual Meeting

Relmada Therapeutics, Inc. (RLMD)